直肠癌放疗后第二癌症风险:3DCRT与VMAT不同高分次方案比较
该回顾性研究对25例直肠癌放疗患者生成VMAT与3DCRT虚拟计划,处方分别为25×1.8 Gy和5×5 Gy,用致癌模型和流行病学数据估算终生归因风险(LAR)。VMAT与3DCRT的总LAR分别为2.3–3.0%与2.0–2.7%,5×5 Gy方案为1.4–1.9%与1.2–1.6%;两者SCR无统计学显著差异,但膀胱和结肠的器官特异性超额LAR在3DCRT下显著更低且差异很小。
要点
- VMAT与3DCRT的总第二癌症LAR无统计学显著差异。
- 膀胱和结肠的器官特异性超额LAR在3DCRT下显著更低但差异小。
- 与大分次25×1.8 Gy相比,5×5 Gy方案的SCR更小。
核心结论
- 使用VMAT或3DCRT未检测到第二癌症风险有统计学显著差异。
- 膀胱和结肠的器官特异性超额LAR在使用3DCRT时统计学更低,但差异很小。
- 与流行病学数据相比,使用大分次方案时SCR更小。
研究设计与样本
- 回顾性评估25例既往接受直肠癌放疗患者的VMAT与3DCRT虚拟治疗计划。
- 处方剂量分别为25×1.8 Gy和5×5 Gy。
- 使用致癌模型和癌与肉瘤诱导的流行病学数据估算SCR,以终生归因风险(LAR)确定。
主要发现
- 平均超额LAR在邻近PTV的器官最高。
- VMAT与3DCRT的总LAR分别为2.3–3.0%和2.0–2.7%。
- 5×5 Gy时VMAT的LAR为1.4–1.9%,3DCRT为1.2–1.6%。
- 器官特异性超额LAR在VMAT下显著更高,膀胱和结肠最高。
- PTV大小和形状影响SCR,年龄≤40岁时最高。
关键数值与推荐
- 对于额外终生风险60年的患者,25×1.8 Gy的LAR为10%,5×5 Gy为6%。
- 正常预期寿命时SCR高2%。
临床怎么用
- 在直肠癌放疗计划选择时,可参考VMAT与3DCRT总SCR无显著差异的结果。
- 对膀胱和结肠等邻近PTV器官,3DCRT的器官特异性超额LAR统计学更低但差异小。
- 大分次方案(5×5 Gy)相比25×1.8 Gy显示更小的SCR。
- 年轻患者(年龄≤40岁)及PTV较大或形状复杂者SCR更高,计划设计需关注。
局限性
- 研究为回顾性虚拟计划评估,样本量为25例。
- SCR基于致癌模型和流行病学数据估算,非直接观察结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate second cancer risk (SCR) comparing volumetric modulated arc therapy (VMAT) and 3D conformal radiotherapy (3DCRT) with different high dose fractionation schemes. METHODS: VMAT and 3DCRT virtual treatment plans for 25 patients previously treated with radiotherapy for rectal cancer were evaluated retrospectively. Doses prescribed were 25 × 1.8 Gy and 5 × 5 Gy, respectively. SCR was estimated using a carcinogenesis model and epidemiological data for carcinoma and sarcoma induction. SCR was determined by lifetime attributable risk (LAR). RESULTS: Mean excess LAR was highest for organs adjacent to the PTV. Total LAR for VMAT and 3DCRT was 2.3-3.0 and 2.0-2.7 %, respectively. For 5 × 5 Gy, LAR was 1.4-1.9 % for VMAT and 1.2-1.6 % for 3DCRT. Organ-specific excess LAR was significantly higher for VMAT, and highest for bladder and colon. Size and shape of the PTV influenced SCR and was highest for age ≤ 40 years. For a patient with an additional lifetime risk of 60 years, LAR was 10 % for 25 × 1.8 Gy and 6 % for 5 × 5 Gy. CONCLUSIONS: No statistically significant difference was detected in SCR using VMAT or 3DCRT. For bladder and colon, organ-specific excess LAR was statistically lower using 3DCRT, however the difference was small. Compared to epidemiological data, SCR was smaller when using a hypofractionated schedule. SCR was 2 % higher at normal life expectancy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT02572362 . Registered 4 October 2015. Retrospectively registered.
引用
- Zwahlen DR, Bischoff LI, Gruber G, et al. Estimation of second cancer risk after radiotherapy for rectal cancer: comparison of 3D conformal radiotherapy and volumetric modulated arc therapy using different high dose fractionation schemes. Radiat Oncol. 2016. PMID: 27832799
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。